Discovery Engines
Discovery Engines
Podcast Description
Featuring the people and platforms accelerating scientific discovery.
Podcast Insights
Content Themes
The podcast covers a variety of topics related to scientific innovation, technology in research, and the deep tech startup ecosystem. Specific episodes explore themes such as the ethics and advancements in animal testing, the cultural shifts in lab automation, and the role of AI in life sciences, with examples including conversations around the founding of Olden Labs and the business structure of Bay Area Lab Automators.
Featuring the people and platforms accelerating scientific discovery. Hosted by Nabil Laoudji. More at www.discoveryengines.co
Gabriele Corso, CEO and co-founder of Boltz, believes the most powerful AI models for drug discovery should be accessible to all, starting with the open models his team has put in the hands of over 100,000 scientists. In this episode, I sit down with Gabriele to explore the leap from predicting protein structures to designing new molecules with Boltz-1, Boltz-2, and BoltzGen, why he champions open access, their multi-year partnership with Pfizer, and the vision of “zero-shot” drug design.
Hosted by Nabil Laoudji. See below for episode links, chapters, and our socials. 🙏🙌
Episode Links:
- Boltz
- Boltz Repository
- Gabriele’s LinkedIn
- Worldwide Protein Data Bank
- Ginkgo Lab Tour
- Pfizer Partnership Announcement
Chapters:
- (00:00) – Preview
- (00:56) – Intro
- (02:15) – Why Proteins Matter and Rational Drug Design
- (05:51) – Target Identification, the Toughest Problem in Drug Discovery
- (07:55) – Small Molecules and Biologics
- (12:57) – Does a Disease Have One Target or Many?
- (15:36) – The Billion Dollar Molecule and How Boltz’s Models Work
- (22:05) – The Protein Data Bank (PDB) and the Role of Sequencing Data
- (25:55) – What New Data Could Improve AI Bio Models?
- (29:02) – Where Boltz’s Training Data Comes From
- (31:46) – Unlocking Private Bio Data
- (35:34) – Boltz’s Open Approach vs. DeepMind’s Isomorphic Labs
- (39:18) – What Boltz’s 100,000 Users Get Access To
- (41:32) – Inside the Pfizer Partnership
- (43:55) – Why Biotech Business Models Are So Hard (Microsoft, Apple, Red Hat)
- (49:17) – How Boltz Differs from Schrödinger, Recursion and Others
- (52:31) – Regulation, the FDA, and Trust in Computational Data
- (56:42) – Autonomous Labs and the Data Feedback Loop
- (1:00:25) – Faster Trials, Virtual Cells, and Other Speedups
- (1:03:34) – When Will a Boltz-Designed Drug Reach a Patient?
- (1:04:55) – How Listeners Can Help (Hiring, Partnerships, Investing)
- (1:06:27) – Closing Reflections on Access
Connect With Us:
Platforms:
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.